Cargando…
Neovascular Age‐Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect
Intravitreal ranibizumab is a first‐line therapy for neovascular age‐related macular degeneration (nAMD), but there is a need to optimize patient outcomes while minimizing treatment burden. Here, we developed an indirect response, nonlinear, mixed effects model of disease progression and drug effect...
Autores principales: | Mulyukov, Zufar, Weber, Sebastian, Pigeolet, Etienne, Clemens, Andreas, Lehr, Thorsten, Racine, Amy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202467/ https://www.ncbi.nlm.nih.gov/pubmed/30043524 http://dx.doi.org/10.1002/psp4.12322 |
Ejemplares similares
-
Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity
por: Feigl, Beatrix, et al.
Publicado: (2007) -
VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION
por: Ceklic, Lala, et al.
Publicado: (2017) -
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany
por: Wachtlin, Joachim, et al.
Publicado: (2020) -
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)